Klinische studies melanoom en andere huidtumoren

Op deze pagina



Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)

MK7684A-010 (KEYVIBE-010)

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)


A Phase 3 Randomized, Double-blind, Placebo- and Active Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with High-risk Stage II-IV Melanoma



Efficacy and Safety of UV1 Vaccination in Combination With Nivolumab and Ipilimumab as First Line Treatment of Patients With Unresectable or Metastatic Melanoma

MONETTE - D533AC00001

A Randomised, Open-Label, Phase 2 Study of Ceralasertib and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanced Melanoma and Primary or Secondary Resistance to PD-(L)1 inhibition


A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma



A Phase Ib/II, Multicenter, Open-label, Dose Escalation Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF V600 - Dependent Advanced Solid Tumors


A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma


A phase II randomized, open-label, multi-arm combinations in previously treated unresectable or metastatic BRAFV600 or NRAS mutant Melanoma


A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma


An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

IMSPIRE170 CO39722

A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma

KEYNOTE-006 MK3475-006

A multicenter, randomized, controlled, two-arm, phase III study to evaluate the safety and efficacy of MK-3475 compared to ipilimumab in patients with advanced melanoma

KEYNOTE-587 MK3475-587

A Multicenter, Open Label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial

KEYNOTE-716 MK3475-716

Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study


An Open-Label, Multicenter, Non-Randomized, Dose confimiation and cohort Expansion Phase lb Study to Evaiuate the Safety, Tolerability, and Anti-Tumor Activity of Nous-PEV, a personalized genetic vaccine composed of a one GAd2O-PEV priming and 3 MVA-PEV boosting administration) with Pembroiizumab as per SoC PD1 inhibitor, in Patients with Stage lii (unresectable) / Stage IV Melanoma cancer or Stage IV NSCLC

MERKLIN2 4SC-202-3-2018

A phase II, open label, multicenter study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced, unresectable Merkel-Cell Carcinoma


A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy


A phase III, double-blinded, randomized, placebo-controlled study of atezolizumab plus cimetinib and vemurafenib versus placebo plus cobimetinib and vemurafenib in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma

Laatste aanpassing: 17 april 2023